ライフサイエンスコーパス: lymphoproliferative disease

1 lar to those found in patients with X-linked lymphoproliferative disease.

2 e of the noncanonical NF-kappaB pathway in B lymphoproliferative disease.

3 om macroglobulinemia is a distinct low-grade lymphoproliferative disease.

4 in whom it can cause life-threatening B cell lymphoproliferative disease.

5 modulatory receptors, is mutated in X-linked lymphoproliferative disease.

6 lects HVL patients at risk of posttransplant lymphoproliferative disease.

7 -4-deficient mice develop fatal, early onset lymphoproliferative disease.

8 viral loads and emergence of EBV-associated lymphoproliferative disease.

9 ne EVR/rTAC patient developed posttransplant lymphoproliferative disease.

10 f adult T-cell leukemia (ATL), an aggressive lymphoproliferative disease.

11 host defect led to a specific and consistent lymphoproliferative disease.

12 e of cytomegalovirus disease and no cases of lymphoproliferative disease.

13 We had no cases of posttransplant lymphoproliferative disease.

14 the human genetic immunodeficiency X-linked lymphoproliferative disease.

15 Epstein-Barr virus-positive post-transplant lymphoproliferative disease.

16 homa, Hodgkin's lymphoma, and posttransplant lymphoproliferative disease.

17 nfections are associated with development of lymphoproliferative disease.

18 ted protein), the protein absent in X-linked lymphoproliferative disease.

19 th of immune control in limiting LCV-induced lymphoproliferative disease.

20 ed, but there was no evidence of LCV-induced lymphoproliferative disease.

21 pus erythematosus that also have features of lymphoproliferative disease.

22 ciated with hypertension, hyperlipidemia, or lymphoproliferative disease.

23 and pathological spectrum of posttransplant lymphoproliferative disease.

24 rowth and the monitoring for post-transplant lymphoproliferative disease.

25 viously reported as a form of posttransplant lymphoproliferative disease.

26 s, and early stem cells and induces a lethal lymphoproliferative disease.

27 eased risk for development of posttransplant lymphoproliferative disease.

28 tient in each group developed posttransplant lymphoproliferative disease.

29 TNF-family receptor result in autoimmune and lymphoproliferative disease.

30 reated before HSCT because of EBV-associated lymphoproliferative disease.

31 entially fatal EBV-associated posttransplant lymphoproliferative disease.

32 many are at increased risk of virus-driven B-lymphoproliferative disease.

33 e targeted in T cell therapy of EBV-driven B-lymphoproliferative disease.

34 ferentiation into effector cells and induced lymphoproliferative disease.

35 sally linked to Kaposi's sarcoma and several lymphoproliferative diseases.

36 etiologic agent of Kaposi's sarcoma (KS) and lymphoproliferative diseases.

37 ses are associated with numerous cancers and lymphoproliferative diseases.

38 ostic information for the development of EBV lymphoproliferative diseases.

39 ndocrine/metabolic diseases, and hematologic/lymphoproliferative diseases.

40 mphocytes and is responsible for a number of lymphoproliferative diseases.

41 llularly could be useful in the treatment of lymphoproliferative diseases.

42 ses infectious mononucleosis and can lead to lymphoproliferative diseases.

43 well-tolerated treatment for autoimmune and lymphoproliferative diseases.

44 cus on the role of TWIST2 in CLL and related lymphoproliferative diseases.

45 in B cells, leading to HCV-associated B-cell lymphoproliferative diseases.

46 ed to the development of both KS and several lymphoproliferative diseases.

47 lue to the etiology of HCV-associated B-cell lymphoproliferative diseases.

48 nt recipients are at risk for development of lymphoproliferative diseases.

49 ation and express B220 as seen in autoimmune lymphoproliferative diseases.

50 etent people, EBV causes several cancers and lymphoproliferative diseases.

51 he role of EBV in the pathogenesis of T-cell lymphoproliferative diseases.

52 can potentially be targeted in autoimmune or lymphoproliferative diseases.

53 in clinical development for treating B-cell lymphoproliferative diseases.

54 lticentric Castleman disease (MCD) and other lymphoproliferative diseases.

55 r the potential development of MCD and other lymphoproliferative diseases.

56 X-linked lymphoproliferative disease 1 (XLP1), due to mutations i

57 ped hematologic malignancies (posttransplant lymphoproliferative diseases, 18; Hodgkin disease, 2; an

58 e causal gene responsible for XLP2 (X-linked lymphoproliferative Disease 2).

59 nce of approximately 80% (49% splenic B-cell lymphoproliferative disease, 28% lymphoma).

60 drome/myeloproliferative neoplasm (19%), and lymphoproliferative diseases (30%).

61 s the genetic locus responsible for X-linked lymphoproliferative disease, a fatal immunodeficiency.

62 Mutations in SH2D1A cause the X-linked lymphoproliferative disease, a primary immunodeficiency.

63 AM-associated protein (SAP) lead to X-linked lymphoproliferative disease, a rare but fatal immunodefi

64 lines to treat EBV-associated posttransplant lymphoproliferative disease, a response rate of 52% was

65 I, 1.03-3.10; P = 0.038) and post-transplant lymphoproliferative disease (adjusted HR, 2.72; 95% CI,

66 is a complex retrovirus associated with the lymphoproliferative disease adult T-cell leukemia/lympho

67 y immunogenic tumors such as post-transplant lymphoproliferative disease, although resistance occurre

68 ls contributes to the pathophysiology of the lymphoproliferative disease and AHA in IL-2-deficient mi

69 These mice developed lymphoproliferative disease and autoimmunity and died pr

70 This mechanism probably contributed to the lymphoproliferative disease and autoimmunity of miR-17-9

71 e discuss this unique form of posttransplant lymphoproliferative disease and briefly review the clini

72 ontaneously mounting a severe autoaggressive lymphoproliferative disease and can modulate immune resp

73 onset of a variety of pathologies, including lymphoproliferative disease and cancers.

74 H2D1A, the gene that is aberrant in X-linked lymphoproliferative disease and familial hemophagocytic

75 ase but not in EBV-associated posttransplant lymphoproliferative disease and Hodgkin disease.

76 mal in 14 of 16 patients (88%) with X-linked lymphoproliferative disease and in 8 of 14 patients (57%

77 In human X-linked lymphoproliferative disease and its gene-targeted mouse

78 r virus (EBV) often induces extensive B-cell lymphoproliferative disease and lymphoma.

79 f in vivo immune control over posttransplant lymphoproliferative disease and lymphomas, our investiga

80 s adoptive immunotherapy against EBV-related lymphoproliferative disease and many other EBV-associate

81 n-Barr virus (EBV)-associated posttransplant lymphoproliferative disease and melanoma.

82 These mice develop a lymphoproliferative disease and occasional transformatio

83 ometimes fatal syndromes, including X-linked lymphoproliferative disease and severe cases of common v

84 h are well-known for their ability to induce lymphoproliferative disease and to establish latency in

85 Epstein-Barr virus-associated posttransplant lymphoproliferative disease and was characterized by the

86 Burkitt lymphoma, nasopharyngeal carcinoma, lymphoproliferative disease and, though still debated, b

87 (KSHV) is the causative agent of two B-cell lymphoproliferative diseases and Kaposi's sarcoma, an en

88 hotropic herpesvirus strongly linked to both lymphoproliferative diseases and Kaposi's sarcoma.

89 rus (KSHV) is involved in the development of lymphoproliferative diseases and Kaposi's sarcoma.

90 ociation of hepatitis C virus infection with lymphoproliferative diseases and, newly, with cholangioc

91 cardiac allografts is limited by rejection, lymphoproliferative disease, and coronary vasculopathy.

92 eration, vascular thrombosis, posttransplant lymphoproliferative disease, and estimated glomerular fi

93 odies to EBV, EBV RNA in lymph nodes, T-cell lymphoproliferative disease, and hemophagocytic lymphohi

94 stromal lymphopoietin levels, milder B-cell lymphoproliferative disease, and improved survival in Ms

95 th everolimus and hemolytic uremic syndrome, lymphoproliferative disease, and proteinuria, and higher

96 cleosis, hemophagocytic lymphohistiocytosis, lymphoproliferative disease, and/or EBV+ B-cell lymphoma

97 erative syndromes, hemophagocytic disorders, lymphoproliferative diseases, and novel differential dia

98 2%, avascular necrosis; 0.2%, posttransplant lymphoproliferative disease; and 0%, polyomavirus.

99 isk of adverse events such as posttransplant lymphoproliferative disease are discussed.

100 Lymphoproliferative diseases are characterized by massiv

101 % of patients with autoimmune, allergic, and lymphoproliferative diseases are refractory to glucocort

102 oncogenesis of Epstein-Barr virus in B-cell lymphoproliferative disease arising in immunosuppressed

103 ponse rates in patients with post-transplant lymphoproliferative disease as well as EBV-positive lymp

104 lls are frequently observed in several other lymphoproliferative diseases as well.

105 ciated with the development of lymphomas and lymphoproliferative diseases, as well as several other t

106 is pathologically similar to posttransplant lymphoproliferative disease associated with Epstein-Barr

107 umvent experimental limitations due to fatal lymphoproliferative disease associated with genetic abla

108 ed sufficient insulin until the mice died of lymphoproliferative disease at 12 months age.

109 echanisms responsible for the induction of a lymphoproliferative disease, atypical lymphoid hyperplas

110 aland black (NZB) mice with autoimmune and B lymphoproliferative disease (B-LPD) are a model for huma

111 cally decreased risks of posttransplantation lymphoproliferative disease but is followed by a prolong

112 Epstein-Barr virus (EBV) posttransplantation lymphoproliferative disease, but the extent of immune de

113 Posttransplant lymphoproliferative disease can be treated by the infusi

114 ce demonstrated a role for Erk activation in lymphoproliferative disease caused by the LAT knock-in m

115 g Pten in Treg cells developed an autoimmune-lymphoproliferative disease characterized by excessive T

116 ced-stage PSC was 18.7%, with posttransplant lymphoproliferative diseases, colorectal cancer, and ren

117 Dianzani autoimmune lymphoproliferative disease (DALD) has a similar phenoty

118 c/prolymphocytic leukemia (T-CLL/T-PLL) is a lymphoproliferative disease derived from immunocompetent

119 ism by which HTLV-1, a virus associated with lymphoproliferative disease, dysregulates common T-cell

120 Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) is a potentially l

121 plantation recipients with biopsy-proven EBV-lymphoproliferative disease (EBV-LPD).

122 te activity can lead to life-threatening EBV lymphoproliferative disease (EBV-PTLD).

123 ologically against inflammatory, immune, and lymphoproliferative diseases for more than 50 years.

124 xp3 leads to development of fatal autoimmune lymphoproliferative disease; furthermore, ectopic Foxp3

125 that depend upon expression of the X-linked lymphoproliferative disease gene product, SH2D1A/DSHP/SA

126 ty genes (RAB27A, LYST, and AP3B1), X-linked lymphoproliferative disease genes (SH2D1A and XIAP), and

127 nd congenic Fas ligand-deficient generalized lymphoproliferative disease (gld) mice were exposed to 7

128 us lymphoproliferation (lpr) and generalized lymphoproliferative disease (gld) mutations exhibit abno

129 teen patients with infections/posttransplant lymphoproliferative disease had a mean ATP of 48 ng/ml.

130 Treatment of posttransplant lymphoproliferative disease has been augmented by the us

131 graft-versus-host disease, or posttransplant lymphoproliferative disease has been observed.

132 arr virus (EBV)-positive posttransplantation lymphoproliferative disease has suggested that such lesi

133 nstrated to promote Treg cell suppression of lymphoproliferative diseases, has an unexpected function

134 r tumors and various forms of posttransplant lymphoproliferative disease have occurred after mTOR con

135 n cancer, Kaposi sarcoma, and posttransplant lymphoproliferative disease have standardized incidence

136 onucleosis or its fatal equivalent, X-linked lymphoproliferative disease; (ii) EBV infection in a ran

137 Marek's disease virus (MDV) causes a deadly lymphoproliferative disease in chickens and modulates me

138 Marek's disease virus (MDV) causes an acute lymphoproliferative disease in chickens, resulting in T

139 as a surprise in this issue of Immunity that lymphoproliferative disease in Foxo3a-deficient mice may

140 in T cell development and leads to a severe lymphoproliferative disease in homozygous knock-in mice.

141 is associated with an increased incidence of lymphoproliferative disease in immunocompromised hosts.

142 n either inhibit or enhance the induction of lymphoproliferative disease in immunocompromised mice.

143 prophylaxis and treatment of EBV-associated lymphoproliferative disease in immunocompromised patient

144 human malignancies including posttransplant lymphoproliferative disease in immunosuppressed patients

145 ayed the onset and decreased the severity of lymphoproliferative disease in LAT knock-in mice.

146 products might suppress MAPK activation and lymphoproliferative disease in LAT mutant mice.

147 reduced expression is a major determinant of lymphoproliferative disease in mice and humans; moreover

148 We report here the development of a CD30+ lymphoproliferative disease in mice lacking the proapopt

149 1 (PLC-gamma1)-binding site leads to a fatal lymphoproliferative disease in mice.

150 and has been reported to be associated with lymphoproliferative disease in mice.

151 The incidence of posttransplant lymphoproliferative disease in patients receiving siroli

152 eutic efficacy of these drugs for EBV-driven lymphoproliferative disease in patients.

153 e effective for the inhibition of EBV-driven lymphoproliferative disease in SCID mice than chemothera

154 d strongly inhibit the growth of EBV-induced lymphoproliferative disease in SCID mice.

155 lignancy in mouse models, and development of lymphoproliferative disease in three individuals with se

156 e and effective prophylaxis or treatment for lymphoproliferative disease in transplantation recipient

157 mechanistic insight into the pathogenesis of lymphoproliferative disease in XLP.

158 ells or isolated CD14 cells induced lymphoma/lymphoproliferative diseases in 74% (20 of 27) of inject

159 Parasites in the genus Theileria cause lymphoproliferative diseases in cattle, resulting in eno

160 is to educate the reader about two cutaneous lymphoproliferative diseases in childhood: pityriasis li

161 of human lymphoid and epithelial tumors and lymphoproliferative diseases in immunocompromised patien

162 tion disrupts T-cell homeostasis and induces lymphoproliferative diseases in mice.

163 i (Saimiriine herpesvirus-2) causes lethal T lymphoproliferative diseases in the susceptible species

164 ases of GI involvement by an indolent T-cell lymphoproliferative disease, including 6 men and 4 women

165 esviral infection is closely associated with lymphoproliferative diseases, including B cell lymphomas

166 opment of Kaposi's sarcoma and several other lymphoproliferative diseases, including primary effusion

167 O mice developed lupus-like autoimmunity and lymphoproliferative disease, indicating that ubiquitin l

168 Kaposi's sarcoma (KS) and lymphoproliferative diseases induced by KS-associated he

169 Epstein-Barr virus (EBV)-induced lymphoproliferative disease is an important complication

170 X-linked lymphoproliferative disease is caused by mutations affec

171 cell therapy for EBV-driven post-transplant lymphoproliferative disease is stimulating efforts to ta

172 Lymphadenopathy in autoimmune and other lymphoproliferative diseases is in part characterized by

173 The role of angiogenesis in lymphoproliferative diseases is not well established.

174 stein-Barr virus (EBV)-driven posttransplant lymphoproliferative disease, is an important goal in cli

175 velopment of three major human neoplastic or lymphoproliferative diseases: Kaposi's sarcoma (KS), pri

176 Individuals with X-linked lymphoproliferative disease lack invariant natural kille

177 V in the pathogenesis of EBV-positive T-cell lymphoproliferative diseases largely unresolved.

178 Scurfy mice develop CD4 T-cell-mediated lymphoproliferative disease leading to death within 4 we

179 ne function; however, treated mice developed lymphoproliferative disease, likely due to viral-promote

180 different centers to prevent or treat EBV(+) lymphoproliferative disease (LPD) arising after hematopo

181 on of these mice (~5%) develop a spontaneous lymphoproliferative disease (LPD) that results in dramat

182 tion are defective in promoting EBV-mediated lymphoproliferative disease (LPD).

183 iates with the development of EBV-associated lymphoproliferative disease (LPD).

184 rare Epstein-Barr virus (EBV)-driven B-cell lymphoproliferative disease (LPD).

185 ymorphic extranodal or (3) polymorphic nodal lymphoproliferative disease (LPD); and (4) diffuse large

186 Immunophenotypes in lymphoproliferative diseases (LPD) are prognostically si

187 Lymphoproliferative diseases (LPDs) associated with the

188 that are associated with the development of lymphoproliferative diseases, lymphomas, as well as othe

189 itt lymphoma and immunocompromise-associated lymphoproliferative diseases/lymphomas as well as epithe

190 pment; however, they rapidly develop a fatal lymphoproliferative disease marked by the uncontrolled e

191 -125b are associated with the development of lymphoproliferative disease, marked by expansion of CD8(

192 ciated with Kaposi sarcoma (KS) and 2 B cell lymphoproliferative diseases, namely primary effusion ly

193 Patients with lymphoproliferative diseases not in CR (except Hodgkin l

194 This acute and lethal lymphoproliferative disease occurs after a prolonged asy

195 Marek's disease (MD) is a lymphoproliferative disease of chickens caused by the on

196 Marek's disease (MD) is a lymphoproliferative disease of chickens induced by a her

197 Marek's disease, a lymphoproliferative disease of chickens, is caused by an

198 The natural killer (NK) type of lymphoproliferative disease of granular lymphocytes (LDG

199 d cell aplasia (PRCA) can be associated with lymphoproliferative disease of granular T lymphocytes (T

200 Chronic NK lymphoproliferative disease of large granular lymphocyte

201 anular lymphocyte (LGL) leukemia is a clonal lymphoproliferative disease of mature T and natural kill

202 Adult T-cell leukemia (ATL) is an aggressive lymphoproliferative disease of poor clinical prognosis a

203 ces malignant catarrhal fever (MCF), a fatal lymphoproliferative disease of ruminants, including catt

204 B-cell-tropic virus associated with various lymphoproliferative diseases of both B-cell and non-B-ce

205 osely related protozoan parasites that cause lymphoproliferative diseases of cattle.

206 These mice do not develop spontaneous lymphoproliferative disease or EAE and are resistant to

207 l confounders or a history of posttransplant lymphoproliferative disease or Epstein-Barr virus; altho

208 duced in T cells from patients with X-linked lymphoproliferative disease or normal T cells transfecte

209 t increase in infection, posttransplantation lymphoproliferative disease, or other side effects, othe

210 cleosis, hemophagocytic lymphohistiocytosis, lymphoproliferative disease, organomegaly, and/or malign

211 cystis carinii pneumonia, and no evidence of lymphoproliferative disease over 1 year.

212 Furthermore, in X-linked lymphoproliferative disease patients, SAP deficiency red

213 Primary CD30+ cutaneous lymphoproliferative disease (PCLPD) is a spectrum of ind

214 ene expression contributes to EBV-associated lymphoproliferative disease, potentially through inducti

215 rcoma and is also associated with two B-cell lymphoproliferative diseases, primary effusion lymphoma

216 describes the development of posttransplant lymphoproliferative disease (PTLD) after allogeneic SpTx

217 es such varied conditions as post-transplant lymphoproliferative disease (PTLD) and Burkitt's lymphom

218 sodes of rejection as well as posttransplant lymphoproliferative disease (PTLD) and graft-versus-host

219 Optimal upfront therapy for posttransplant lymphoproliferative disease (PTLD) arising after solid o

220 more than 1000 copies/mL and posttransplant lymphoproliferative disease (PTLD) developed in 2 of the

221 city (p = 0.014) and previous posttransplant lymphoproliferative disease (PTLD) diagnosis (p = 0.006)

222 -Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) encompasses a histolo

223 nsplant Epstein-Barr virus-associated B-cell lymphoproliferative disease (PTLD) has a higher incidenc

224 PURPOSE Adult post-transplantation lymphoproliferative disease (PTLD) has a reported 3-year

225 the incidence and hazard for posttransplant lymphoproliferative disease (PTLD) in a study of 3170 pe

226 Posttransplant lymphoproliferative disease (PTLD) is a common Epstein-B

227 virus (EBV)-associated post-transplantation lymphoproliferative disease (PTLD) is a common, often fa

228 Epstein-Barr virus-associated posttransplant lymphoproliferative disease (PTLD) is a life-threatening

229 Posttransplant lymphoproliferative disease (PTLD) is a major complicati

230 Posttransplantation lymphoproliferative disease (PTLD) is a major complicati

231 Posttransplant lymphoproliferative disease (PTLD) is a serious complica

232 Posttransplant lymphoproliferative disease (PTLD) is a serious complica

233 Posttransplantation lymphoproliferative disease (PTLD) is an often Epstein-B

234 tients with EBV-positive posttransplantation lymphoproliferative disease (PTLD) on the basis of the b

235 Optimal therapy for posttransplant lymphoproliferative disease (PTLD) remains problematic.

236 Optimal management of posttransplant lymphoproliferative disease (PTLD) remains to be defined

237 irus (EBV) is associated with posttransplant lymphoproliferative disease (PTLD), and EBV load measure

238 ding Burkitt's lymphoma (BL), posttransplant lymphoproliferative disease (PTLD), nasopharyngeal carci

239 d III latency tumors, such as posttransplant lymphoproliferative disease (PTLD), on EBV I latency tum

240 o several diseases, including posttransplant lymphoproliferative disease (PTLD), which involves very

241 risk for EBV-associated posttransplantation lymphoproliferative disease (PTLD).

242 months after implantation for posttransplant lymphoproliferative disease (PTLD).

243 ein Barr virus (EBV)-positive posttransplant lymphoproliferative disease (PTLD).

244 alovirus (CMV) infection, and posttransplant lymphoproliferative disease (PTLD).

245 central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD).

246 ant recipients are at risk of posttransplant lymphoproliferative disease (PTLD).

247 infections and trigger post-transplantation lymphoproliferative disease (PTLD).

248 everal interventions can cure posttransplant lymphoproliferative disease (PTLD); a sequential approac

249 Posttransplantation lymphoproliferative diseases (PTLD) are mainly Epstein-B

250 tein-Barr virus (EBV)(+) posttransplantation lymphoproliferative diseases (PTLD) in cord blood transp

251 y, and EBV-related morbidity (posttransplant lymphoproliferative disease [PTLD] or symptomatic EBV in

252 , and Epstein-Barr virus) and posttransplant lymphoproliferative disease remained low.

253 eficiency with a loss of Ripk3 gives rise to lymphoproliferative disease reminiscent of lpr or gld mi

254 We analyzed the virological and lymphoproliferative disease response (LDR) of 46 patient

255 characterized by the progression of a T-cell lymphoproliferative disease (restricted to BM and lympho

256 ribed patients with immune dysregulation and lymphoproliferative disease resulting from 2 different g

257 and encoded by Foxp3) causes a rapidly fatal lymphoproliferative disease, similar to that seen in mic

258 c T-lymphocyte epitopes in 25 posttransplant lymphoproliferative disease specimens from 19 patients.

259 entiviruses cause an incurable, progressive, lymphoproliferative disease that affects millions of ani

260 granular lymphocytic leukaemia (T-LGL) is a lymphoproliferative disease that presents with immune-me

261 tive for CAEBV, even in patients with active lymphoproliferative disease that was unresponsive to che

262 Hairy cell leukemia (HCL) is a chronic lymphoproliferative disease, the cause of which is unkno

263 xposure to these medications and the risk of lymphoproliferative disease, the known predisposition of

264 In type III latency, exemplified by EBV lymphoproliferative diseases, the full range of these vi

265 unopathology of IM in boys with the X-linked lymphoproliferative disease trait, and as a chronic acti

266 Barr virus strains present in posttransplant lymphoproliferative disease tumors.

267 en), poor compliance (three), posttransplant lymphoproliferative disease, (two), hepatocellular carci

268 aturally infects rhesus macaques and induces lymphoproliferative diseases under experimental conditio

269 Sixty-five patients with lymphoproliferative diseases underwent sibling (n = 57)

270 t HTLV-1, an etiologic agent associated with lymphoproliferative diseases, uses a conserved accessory

271 ity using B6(mir146a-/-) mice and a model of lymphoproliferative disease using the well-characterized

272 ity allogeneic stem cell transplantation for lymphoproliferative diseases using a BEAM-alemtuzumab pr

273 EBV-related posttransplant lymphoproliferative disease was not observed up to 12 mo

274 ne (1.7%) case of polymorphic posttransplant lymphoproliferative disease was seen, which regressed wi

275 y determine the role of Erk in this delay of lymphoproliferative disease, we also bred a transgenic,

276 aired in T cells from patients with X-linked lymphoproliferative disease, which lack SLAM-associated

277 The boy developed posttransplant lymphoproliferative disease, which resolved after treatm

278 igh-risk recipients developed EBV-associated lymphoproliferative disease, while 2 of the subjects had

279 h adult T-cell leukemia (ATL), an aggressive lymphoproliferative disease with a dismal prognosis.

280 Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease with a highly variable outco

281 ed homeostatic expansion, which manifests as lymphoproliferative disease with autoantibody production

282 s-like and one Burkitt's-like posttransplant lymphoproliferative disease) with restricted viral gene

283 X-linked lymphoproliferative disease (XLP) is a congenital immuno

284 X-linked lymphoproliferative disease (XLP) is a primary immunodef

285 X-linked lymphoproliferative disease (XLP) is a rare congenital i

286 X-linked lymphoproliferative disease (XLP) is a rare immune disor

287 One of the manifestations of X-linked lymphoproliferative disease (XLP) is progressive agammag

288 Patients with X-linked lymphoproliferative disease (XLP) lack such class-switch

289 C4 mutations, is described to cause X-linked lymphoproliferative disease (XLP) phenotypes.

290 (SAP), is altered in patients with X-linked lymphoproliferative disease (XLP), a primary immunodefic

291 The human genetic disease X-linked lymphoproliferative disease (XLP), which is caused by mu

292 s with the primary immunodeficiency X-linked lymphoproliferative disease (XLP), which is caused by mu

293 Seventeen individuals with X-linked lymphoproliferative disease (XLP), who harbored germline

294 T cells from patients with X-linked lymphoproliferative disease (XLP), who lack functional S

295 ients with the clinical syndrome of X-linked lymphoproliferative disease (XLP).

296 ible for the human genetic disorder X-linked lymphoproliferative disease (XLP).

297 ls from SAP-deficient patients with X-linked lymphoproliferative disease (XLP).

298 X-linked lymphoproliferative disease (XLP1) arises from mutations

299 ergistic signalling is defective in X-linked lymphoproliferative disease (XLP1) NK cells entailing 2B

300 X-linked lymphoproliferative disease (XLP1), described in the mid